Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of “Hold” from Brokerages

Moderna, Inc. (NASDAQ:MRNA) has been assigned an average rating of “Hold” from the twenty-three analysts that are currently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $53.58.

Several brokerages recently issued reports on MRNA. Citigroup began coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price target for the company. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, June 2nd. Morgan Stanley decreased their price target on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 9th. JPMorgan Chase & Co. decreased their price target on shares of Moderna from $33.00 to $26.00 and set an “underweight” rating for the company in a research note on Thursday, May 22nd. Finally, Evercore ISI decreased their price target on shares of Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a research note on Friday, May 2nd.

Institutional Trading of Moderna

Large investors have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB grew its stake in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares during the period. S Bank Fund Management Ltd bought a new stake in shares of Moderna in the first quarter worth approximately $25,000. Venturi Wealth Management LLC grew its stake in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares during the period. Compass Planning Associates Inc bought a new stake in shares of Moderna in the fourth quarter worth approximately $37,000. Finally, Crowley Wealth Management Inc. bought a new stake in shares of Moderna in the fourth quarter worth approximately $41,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Trading Down 1.6%

NASDAQ:MRNA opened at $27.68 on Friday. The company has a 50-day moving average price of $26.16 and a 200-day moving average price of $33.31. Moderna has a 12 month low of $23.15 and a 12 month high of $150.74. The stock has a market cap of $10.71 billion, a price-to-earnings ratio of -2.98 and a beta of 1.86.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping the consensus estimate of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to analysts’ expectations of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company’s quarterly revenue was down 35.3% compared to the same quarter last year. During the same period last year, the company posted ($3.07) EPS. Equities analysts forecast that Moderna will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.